Immunomodulation of Potent Antioxidant Agents: Preclinical Study to Clinical Application in Multiple Sclerosis

Shyi-Jou Chen^{1,2} Hueng-Chuen Fan¹ and Huey-Kang Sytwu^{2,*}

¹*Department of Pediatrics, Tri-Service General Hospital*

²*Department of Microbiology and Immunology
National Defense Medical Center
Taiwan (ROC)*

1. Introduction

Multiple sclerosis (MS) is a chronic disease of the central nerve system (CNS) primarily affecting youngsters. The CNS has a potent antioxidant defense mechanism to scavenge reactive oxygen species (ROS). MS can be effectively studied in animal models with experimental autoimmune encephalomyelitis (EAE). The immunopathogenic mechanisms involved in EAE are attributed to T-cell-mediated inflammatory disease of the CNS and activation of T cells, which recruit invading inflammatory cells, such as macrophages. The activated T cells also induce astrocytes and microglia in situ to secrete cytokines, chemokines, and toxic molecules, namely, glutamate, nitric oxide (NO), and/or ROS, which in turn contribute to axonal damage. These processes are followed by complement activation and antibody-mediated phagocytosis of axons, which eventually lead to demyelination and axonal injury.

Brain tissue of MS patients was found to express antioxidants, and MS lesions have been reported to express high levels of antioxidants, indicating oxidative stress (OS). Heme oxygenase-1 (HO-1) is a heat-shock protein induced by OS; this protein was found to be expressed in active MS lesions and in EAE. Therefore, it can be inferred that ROS may play a distinct role in the pathogenesis of MS and that antioxidants may inhibit the development and progression of MS lesions. In this chapter, we summarize immunomodulation and therapeutic strategies in MS and examine experimental and clinical evidence to assess the applicability of the novel strategy of using antioxidants, such as melatonin, statins, α -lipoic acid (ALA), natural compounds (flavonoids), and erythropoietin (EPO), as adjuvant treatment in MS.

2. Roles of OS in MS

The initial stages of the formation of MS lesions are primarily characterized by the activation of residential microglia by autoreactive Th cells, while the active phase of the MS lesion is

* Corresponding Author

Conflict of interest: The authors declare that no conflict of interest exist

characterized by the infiltration of the lesion area by monocyte-derived macrophages, which initiate demyelination [Schreiner et al., 2009; van der Valk and De Groot, 2000]. Both activated microglia and infiltrated macrophages can generate excessive amounts of proinflammatory mediators and oxidizing radicals, such as superoxide, hydroxyl radicals, hydrogen peroxide, and NO [Colton and Gilbert, 1993; Gilgun-Sherki et al., 2004]. MS is most commonly studied in animal models of EAE. The immunopathogenesis of EAE is widely believed to involve T-cell-mediated inflammatory disease of the CNS, wherein activated T cells recruit macrophages and resident astrocytes and microglia, leading to the release of inflammatory mediators and cytotoxic molecules, namely, glutamate, NO, and/or ROS, which contribute to axonal damage; this is then followed by complement activation or antibody-mediated phagocytosis of axons [Hisahara et al., 2003; Schreibelt et al., 2007]. Furthermore, axonal degeneration in MS lesions can be divided into 2 steps: an initial stage of acute axonal injury in the inflammatory MS lesion [Ferguson et al., 1997; Trapp et al., 1998] and subsequent “slow burning” or axonal degeneration in non-inflammatory chronic lesions [Kornek et al., 2000]. The pathological changes in MS are also characterized by the presence of demyelinating plaques within the gray matter [Frohman et al., 2006]. Nevertheless, mitochondrial dysregulation and mitochondria-derived ROS have been reported to contribute to axonal damage in MS [Kalman et al., 2007; Mahad et al., 2009; Su et al., 2009; van Horssen et al., 2010; Witte et al., 2009]. In addition, a subset of activated microglia was found in cortical lesions, suggesting that microglia-derived ROS might contribute to gray matter demyelination [Gray et al., 2008]. Taken together, these evidences indicate that ROS play a pivotal role in several processes underlying the formation and persistence of MS lesions.

Experimental animal studies have demonstrated that the dietary intake of exogenous antioxidants, including flavonoids and α -lipoic acid, reduces the progression and clinical signs of EAE [Chaudhary et al., 2006; Hendriks et al., 2004; Marracci et al., 2002; Theoharides, 2009; Verbeek et al., 2005]. Despite promising results observed in animal models of MS, data on successful antioxidant therapy in MS patients is still limited; this emphasizes the need for epidemiological and clinical studies on this treatment strategy in MS. Reports indicate that antioxidants need be administered in high quantities to exert their protective effects in animal models of MS [Gilgun-Sherki et al., 2004; Mirshafiey and Mohsenzadegan, 2009]. Since ROS play a pivotal role in the initial phase as well as the chronic stage of MS, antioxidant therapy may be suitable for limiting overall disease progression. Thus, further understanding of the immunomodulatory activities of potential protective antioxidants is vital for their application in MS [Schreibelt et al., 2007; van Horssen et al.].

2.1 HO-1 in EAE/MS

HO-1 is a heat-shock protein induced by OS. In HO-1-expressing cells, the association of reductase with HO-1 competitively limits the interaction of reductase with cytochrome P450 isozymes, and thereby, the resultant production of superoxide; this reduced interaction limits free radical production and prevents oxidative damage of DNA, thereby suppressing oxidative or proinflammatory tissue damage [Prawan et al., 2005]. HO-1 has both antioxidative and anti-inflammatory activities and is highly inducible by a variety of stimuli, including its substrates heme and OS [Schipper, 2004]. Lee and Chau demonstrated that the

overexpression of HO-1 in macrophages can inhibit proinflammatory response via lipopolysaccharide (LPS) stimulation and that IL-10 and HO-1 activate a positive feedback circuit to enhance the anti-inflammatory response both in vitro or in vivo [Lee and Chau, 2002]. In addition, Ponomarev et al. found that increased expression of IL-4 in glial cells was associated with reduced severity of EAE and that IL-4 production in the CNS is crucial for controlling autoimmune inflammation by inducing an alternative pathway for the regulation of microglial cells, but IL-4 production in the peripheral circulation was not found to have this effect [Ponomarev et al., 2007]. In contrast, Lee and Suk showed that IL-10 and IL-4 levels did not have any effect on the overexpression of HO-1 in LPS-stimulated microglia in vitro [Lee and Suk, 2007]. However, Zenclussen et al. found that the upregulation of HO-1 by using an adenoviral vector system expressing the HO-1 gene (AdHO-1) has a protective effect against fetal rejection in the murine abortion model; they also found that compared to abortion-prone mice, AdHO-1-treated mice showed higher values of the systemic and local IL-4/IFN- γ ratios and the IL-10/TNF- α ratio in the spleen [Zenclussen et al., 2006].

HO-1 has been detected in EAE lesions, and significant amplification of HO-1 protein levels has been proved in animal models of EAE [Schluesener and Seid, 2000]. HO-1 expression has also been reported in active MS lesions [van Horssen et al., 2008]. This enhanced expression of endogenous HO-1 may be one of the mechanisms involved in minimizing tissue damage in EAE [Emerson and LeVine, 2000]. Evidence has also shown that Hmox1(-/-) C57BL/6 mice, i.e., HO-1 gene knockout mice, displayed greater severity of EAE as compared to Hmox1(+/+) mice. Further, induction of HO-1 by cobalt protoporphyrin IX (CoPPiX) administration has been shown to suppress EAE progression, but this protective effect of CoPPiX was abrogated in Hmox1(-/-) mice with EAE [Chora et al., 2007]. Thus, endogenous HO-1 expression may play an important protective role in EAE, and therefore, the induction of HO-1 overexpression may represent a novel therapeutic strategy for MS [Liu et al., 2001].

2.2 Inflammation and immunopathogenesis of ROS and NO in MS

Brain tissue is very vulnerable to free radical damage because of its high oxygen utilization (20% of the total oxygen inspired); high concentrations of polyunsaturated fatty acids [Floyd and Hensley, 2002] and transition metals, such as iron, which are involved in the generation of the hydroxyl radical [Hill and Switzer, 1984]; and low concentrations of cytosolic antioxidants [Floyd and Carney, 1993; Reiter, 1995b]. In the brain, NO plays crucial roles in neuromodulation, neurotransmission, maintenance of synaptic plasticity, etc., and it also mediates pathological processes such as neurodegeneration and neuroinflammation [Golde et al., 2002]. Thus, NO may inhibit neuronal respiration, and NO production by astrocytes is believed to contribute to the neurodegenerative process via the impairment of mitochondrial function.

In addition, neuronal injury has also been reported to be associated with NO released by glial cells [Bal-Price and Brown, 2001; Mander et al., 2005]. Although glial activation can be protective, excess activation can be detrimental [Murphy, 1999]. Glia are activated by inflammatory mediators and express new proteins such as inducible NO synthetase (iNOS) [Emerit et al., 2004]. NO produced by the action of iNOS appears to be a key mediator of

glia-induced neuronal death. Astroglial cells are “activated” in a wide range of CNS disorders, leading to the induction of iNOS [Bolanos et al., 1997; Endoh et al., 1994]. In mouse models of EAE, immunohistochemistry revealed elevated activity levels of iNOS in inflammatory lesions of the CNS, suggesting that excessive NO production due to activity of iNOS may play an essential role in eradicating inflammatory cells in the CNS of mice with EAE [Okuda et al., 1997].

A chronic inflammatory state gives rise to an activated immune response, which involves an acute phase protein response and the release of proinflammatory cytokines, macrophages, lymphocytes, and other immune system cells [Murakami, 2009; Taupin, 2008]. This complicated process triggers the recruitment of innate immune cells, which in turn mediates demyelination and axonal damage, and the formation of lesions that generally consist of T cells, macrophages, and microglia. OS plays a critical role in the pathogenesis of MS. ROS, which are generated in excess amounts mainly by macrophages subjected to OS, have been implicated in the demyelination and axonal damage occurring in both MS and EAE [Gilgun-Sherki et al., 2004]. NO has also been identified in the spinal cords of mouse models of EAE, indicating the potential role of NO in the pathogenesis of EAE, and possibly MS [Lin et al., 1993].

Increased levels of the indicators of OS and/or decreased levels of antioxidant enzymes and antioxidants have been detected in the blood and cerebrospinal fluid of MS patients in the active phases of the disease; these findings indicate that increased levels of ROS may cause the depletion of cellular antioxidants [van der Goes et al., 1998; van Horsen et al., 2010; van Meeteren et al., 2005]. In recent decades, immunologic cascade and inflammation have been proposed as causative factors of neurological diseases and autoimmune disorders, such as MS [Taupin, 2008]. On the basis of currently available findings, we assessed the usefulness of statins, melatonin, ALA, natural antioxidant compounds, and EPO, as potential candidates for adjuvant therapy in MS patients, by virtue of for their antioxidant and immunomodulatory proprieties.

3. Statins in MS/EAE

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (or statins) are powerful cholesterol-lowering drugs, which are beneficial to the primary and secondary prevention of coronary heart disease; these drugs can improve endothelial function, increase NO bioavailability, exhibit antioxidant activity, stabilize atherosclerotic plaques, regulate progenitor cells, inhibit inflammatory responses, and exert immunomodulatory effects [Endres, 2006]. Pahan et al. reported that lovastatin inhibits the induction of iNOS and expression of proinflammatory cytokines in rat primary glial cells (astroglia and microglia) and macrophages [Pahan et al., 1997]. Subsequently, Stanislaus et al. showed that proinflammatory cytokines and iNOS are involved in the pathogenesis of EAE [Stanislaus et al., 1999] and thus highlighted the therapeutic importance of lovastatin in inhibiting the neuroinflammatory processes in the CNS and the central expression of iNOS, TNF- α , and IFN- γ in EAE; this suggests that lovastatin may have therapeutic potential in the treatment of neuroinflammatory diseases, such as MS [Stanislaus et al., 1999].

Atorvastatin exhibits pleiotropic immunomodulatory activity against both antigen-presenting cells (APC) and T-cell compartments. For instance, Youssef et al. reported that

atorvastatin treatment of microglia inhibits IFN- γ -inducible transcription of multiple major histocompatibility complex (MHC) class II transactivator (CIITA) promoters and suppresses the upregulation of class II MHC [Youssef et al., 2002]. In addition, they found that atorvastatin suppresses IFN- γ -inducible expression of CD40, CD80, and CD86 co-stimulatory molecules, as well as L-mevalonate, thereby indicating that statins may be beneficial in the treatment of MS and other Th1-mediated autoimmune diseases [Youssef et al., 2002].

Nath et al. demonstrated that lovastatin inhibits EAE by modulating T-cell as well as APC responses and that the effects of lovastatin on macrophage/microglia in an Ag-non-specific system suggest that lovastatin is not only effective in EAE. Their study also revealed that lovastatin inhibits the transcription factors T-bet, NF- κ B, and STAT4, which are responsible for CNS inflammation, via the induction of Th1 cell differentiation and production of related cytokines, such as IFN- γ and TNF- α . In addition, lovastatin induces the expression of GATA3 and STAT6 in Th2 cells and contributes to the downregulation of IFN- γ /T-bet in Th1 cells [Nath et al., 2004]. Statins have been reported to have potential for use as novel therapeutic agents to reverse the established paralysis in MS and to exert beneficial effects in synergy with other agents already approved for MS therapy [Weber and Zamvil, 2008]. However, simvastatin administered along with interferon β -1a as add-on therapy for at least 1–3 years in patients with relapsing–remitting MS (SIMCOMBIN study) did not show any beneficial effects in a placebo-controlled randomized phase 4 clinical trial [Sorensen et al.]. Similarly, a cohort study revealed that the disability progression in MS did not differ significantly between MS patients receiving and those not receiving statin therapy, thereby suggesting that statins do not affect the long-term course of MS [Paz Soldan et al.]. However, the combination of other statins with other disease-modifying drugs may be beneficial in MS. More clinical data is required to clarify this issue.

4. Melatonin in MS/EAE

Melatonin (5-methoxy-*N*-acetylserotonin) is mainly produced in the pineal gland during the dark phase of the day-night cycle, and it displays multifunctional properties and characteristics of a potent antioxidant [Martin et al., 2000]. In addition, melatonin is involved in the regulation of aging [Pierpaoli and Regelson, 1994] and scavenging of free hydroxyl radicals [Reiter, 1995a]. Melatonin is now well-known as a powerful antioxidant; an increasing number of experimental evidences have shown its protective effects against OS-induced macromolecular damage and diseases, including those involving mitochondrial dysfunction [Acuna et al., 2002]. Furthermore, melatonin exhibits both direct and indirect antioxidant activity, scavenges free radicals, stimulates antioxidant enzymes, enhances the activities of other antioxidants, and protects other antioxidant enzymes from oxidative damage [Castroviejo et al., 2011; Esposito and Cuzzocrea, 2010].

The results of numerous clinical studies have indicated that melatonin is a neuroprotective molecule in neurodegenerative disorders, which are believed to involve widespread brain oxidative damage [Esposito and Cuzzocrea, 2010; Kaur and Ling, 2008]. For example, melatonin defeats neurally derived free radicals and reduces the associated neuromorphological and neurobehavioral damage [Reiter et al., 2007]. Melatonin inhibits the expression of the iNOS in murine macrophages by inhibiting NF- κ B activation [Gilad et al., 1998] and suppressing the levels of intercellular adhesion molecule (ICAM)-1 in

experimental spinal cord reperfusion injury [Cuzzocrea et al., 2000]. Constantinescu et al. reported that melatonin is capable of immunomodulation via the activation of NK cells [Constantinescu et al., 1997], upregulation of Th2 response, and inhibition of NF- κ B [Maestroni, 1995]. Thus, both experimental and clinical data show that melatonin reduces the expression of adhesion molecules and pro-inflammatory cytokines and modifies serum inflammatory parameters.

Since the abovementioned findings indicate that melatonin exhibits both anti-inflammatory and immunomodulatory activities, it can be considered effective in suppressing autoimmune diseases, including EAE [Constantinescu, 1995; Sandyk, 1997]. Moreover, Kang et al. demonstrated that melatonin ameliorates EAE through the suppression of ICAM-1 levels. They also reported that melatonin treatment increases T-cell proliferation in mice and enhances the production of NK cells and monocytes in the bone marrow of mice, suggesting that it plays an important role in the immune system; thus, exogenous melatonin has been shown to ameliorate EAE by reducing the expression of ICAM-1 and lymphocyte function-associated antigen-1a (LFA-1 α) in autoimmune target organs [Kang et al., 2001]. On the other hand, Maestroni et al. showed that melatonin treatment of mice decreases the expression of IL-2 and IFN- γ and upregulates the expression of Th2 cell cytokines, such as IL-4 and IL-10 [Maestroni, 1995]. Lin et al. found that melatonin prolongs islet graft survival in nonobese diabetic (NOD) mice via the reduction of Th1 cell and T-cell proliferation and elevating IL-10 levels, thereby indicating that melatonin treatment suppresses autoimmune recurrence after graft implantation [Lin et al., 2009]. Thus, melatonin plays a role in immunomodulation by regulating cytokine production of immunocompetent cells. From these findings, melatonin may be considered effective in improving the clinical course of autoimmune inflammatory diseases.

A clinical study by Akpinar et al. revealed that nocturnal serum melatonin levels were associated with major depression in acute MS patients, suggesting that melatonin deficiency may contribute to the occurrence of depression in MS patients [Akpinar et al., 2008b]. Moreover, Anderson et al. demonstrated that the optimization of melatonin and vitamin D3 inhibits the effects of IL-18 on the symptoms and cell loss of MS, as well as microglia and T-cell activation [Anderson and Rodriguez, 2011]. In addition, they confirmed that valproate treatment may interact significantly with melatonin and vitamin D3 to inhibit seizures and other signs and symptoms of MS [Anderson and Rodriguez, 2011]. Thus, the understanding of the immunomodulatory and anti-oxidative activity of melatonin in EAE may enable the therapeutic application of this molecule in MS.

5. ALA in MS/EAE

ALA (or 1,2-dithiolane-3-pentanoic acid) is a naturally occurring dithiol compound synthesized enzymatically in the mitochondrion from octanoic acid (Curr. Med. Chem. 11 (2004) 1135-1146); it is an essential cofactor of key mitochondrial enzymes that control glucose oxidation, such as pyruvate dehydrogenase and α -ketoglutarate dehydrogenase [Gohil et al., 1999]. ALA mainly acts as a natural antioxidant that scavenges ROS and regenerates or recycles endogenous antioxidants (Free Radic. Res. 20 (1994) 119-133.). ALA and its reduced dithiol form, dihydrolipoic acid (DHLA), are potent antioxidants in both fat- and water-soluble media. In addition, ALA reacts with superoxide and hydroxyl radicals, hypochlorous acid, peroxy radicals, and singlet oxygen [Marangon et al., 1999]. ALA also

recycles vitamins C and E and increases the intracellular glutathione concentration. The antioxidative effect of ALA may be partially mediated by the chelation of transition metals, modification of the redox status of thiol-containing proteins, and inhibition of redox-sensitive nuclear transcription factors [Abdul and Butterfield, 2007; Akpinar et al., 2008a; Moini et al., 2002]. Tirosh et al. have previously shown that LA-plus is a potent protector of neuronal cells against glutamate-induced cytotoxicity and associated oxidative damage [Tirosh et al., 1999]. Further, Cheng et al. reported that ALA protects the cardiovascular system against oxidative injury` [Cheng et al., 2006]. They also found that ALA significantly increased the expression levels of HO-1 and ROS production and increased HO activity in A10 cells and the resistance of A10 cells to hydrogen-peroxide-induced OS; this effect was blocked by *N*-acetyl-cysteine, which also inhibited ALA-induced activation of p44/42 mitogen-activated protein kinase (MAPK) and AP-1, HO-1 expression, and HO activity. These findings suggest that ALA induces HO-1 expression through the production of ROS and subsequent activation of the p44/42 MAPK pathway and AP-1 in vascular smooth muscle cells and that it increases the expression of HO-1, which is a critical cytoprotective molecule [Cheng et al., 2006].

van der Goes et al. reported that ROS appear to be involved in the regulation of the phagocytosis of myelin and that lipoic acid (LA), a non-specific scavenger of ROS, also decreased the phagocytosis of myelin by macrophages [van der Goes et al., 1998].

Marracci et al. have shown that ALA ameliorates EAE in SJL mice immunized with proteolipid protein (PLP) 139-151 peptide, resulting in minimal inflammation characterized by less demyelination and only mild axonal loss in the spinal cords; they also demonstrated a marked reduction in the expression of CD3⁺ T cells and CD11b⁺ monocyte/macrophage cells in the affected spinal cord. Further, ALA and its reduced form, DHLA, inhibited the activity of matrix metalloproteinase-9 (MMP-9) in a dose-dependent manner [Marracci et al., 2002]. This was associated with a reduction in the number of CNS-infiltrating T cells and macrophages as well as decreased demyelination. Morini et al. further tested ALA in a therapeutic protocol aimed at suppressing myelin oligodendrocyte glycoprotein (MOG)-EAE; they also found significant reduction of demyelination and inflammatory infiltration and in the number of MOG-specific T cells, resulting in decreased production of IFN- γ and IL-4; this suggests that ALA exerts immunosuppressive activity on both Th1 and Th2 cytokines [Morini et al., 2004].

Marracci et al. showed that both ALA and DHLA inhibited Jurkat cell migration and have different mechanisms for inhibiting MMP-9 activity. These data together with the finding that ALA can ameliorate relapsing EAE suggest that ALA merits investigation as a therapeutic agent for MS [Marracci et al., 2004]. Moreover, Schreibelt et al. reported that antioxidant LA dose-dependently prevented the clinical development of EAE in a rat model of MS, along with a decrease in the CNS infiltration of leukocytes, particularly monocytes, which may be reflected as reduced ability to cross the blood brain barrier (BBB) [Schreibelt et al., 2006].

Accordingly, oxidative injury is recognized as an important process in the pathogenesis of MS. The powerful antioxidant property of ALA may render it a good candidate for adjuvant treatment in EAE/MS. In addition, ALA is greatly effective in suppressing and treating EAE; this effect is mediated by the inhibition of T-cell trafficking into the spinal cord,

possibly by inhibiting MMP. Thus, ALA impedes the development of EAE not only by serving as an antioxidant but also by affecting the migratory capacity of monocytes and by stabilizing the BBB; these features make ALA an attractive therapeutic agent for MS

6. Potential of natural food compounds in the treatment of EAE/MS

Aktas et al. reported that the green tea extract epigallocatechin-3-gallate (EGCG) reduced the clinical severity of EAE when administered at the initiation or after the onset of the condition; this effect of EGCG is believed to be mediated by the limiting of brain inflammation and reducing neuronal damage, which are mediated by NF-kappa B inhibition, abrogated proliferation and TNF-alpha production of encephalitogenic T cells, and direct blocking of the formation of neurotoxic ROS in neurons [Aktas et al., 2004]. Thus, natural green tea components that have antioxidant, anti-inflammatory, and neuroprotective activities, may be considered novel candidates for the treatment of MS.

6.1 Natural compounds repress MMP to protect EAE/MS

Hendriks et al. have shown that flavonoids, which are naturally occurring compounds of green tea, can influence myelin phagocytosis by macrophages in vitro. The flavonoids luteolin, quercetin (3,3',4',5,7-pentahydroxy flavone), and fisetin most significantly reduce the extent of invasion of myelin phagocytes, without affecting their viability; this implies that they may be capable of restricting the demyelination process involved in MS [Hendriks et al., 2003]. On similar lines, Theoharides found that luteolin and structurally similar flavonoids can inhibit EAE and suggested that an appropriate luteolin formulation that permits sufficient absorption and reduces its metabolism could be a useful adjuvant to IFN- β in the treatment of MS [Theoharides, 2009]. A study by Muthian et al. on SJL/J mouse models of EAE revealed that quercetin (QRC), a flavonoid phytoestrogen, ameliorates EAE in vivo by inhibiting IL-12 production and neural antigen-specific Th1 differentiation and by reducing the MMP-9/TIMP-1 ratio. They further reported that when QRC was used in combination with IFN- β , it has additive effects on the regulation of the levels of TNF- α and MMP-9 [Sternberg et al., 2008]. The enzymes gelatinases A (MMP-2) and B (MMP-9) are involved in the pathogenesis of MS [Bever and Rosenberg, 1999; Mandler et al., 2001]. Liuzzi et al. reported that the non-flavonoids resveratrol (RSV) and tyrosol/hydroxytyrosol (Oliplus), but not the flavonoids QRC and catechins [green tea extract (GTE)], dose-dependently inhibit the expression of MMP-2 and MMP-9 in LPS-activated primary rat astrocytes. In turn, the direct inhibition of MMP2 and MMP-9 was achieved completely by QRC and GTE, not by RSV, and only partially by oliplus in cell-free systems of MS sera. These results indicate that the flavonoids and non-flavonoids tested exert their inhibitory effect on MMPs, displaying different mechanisms of action, possibly related to their structure; this indicates that their combined use may represent a powerful tool for the downregulation of MMPs in the course of MS [Liuzzi et al.,].

6.2 Fumarate linking to Nrf2 pathway to protect MS

The antioxidant-responsive element (ARE) is an enhancer element that triggers the transcription of a battery of genes encoding phase II detoxification enzymes [Rushmore et al., 1991; Rushmore and Pickett, 1990] and factors vital for neuronal survival [Lee et al.,

2005]. The ARE is activated through the binding of its transcription factor NF-E2-related factor 2 (Nrf2) [Moi et al., 1994; Venugopal and Jaiswal, 1996]. Nrf2-ARE activation is a critical neuroprotective pathway that confers resistance to a variety of oxidative, stress-related, neurodegenerative injuries [Johnson et al., 2008]. Evidentially, autopsy studies of MS-affected tissue have revealed that neuronal Nrf2 is also activated during the natural course of MS, which is similar to the observations made in untreated EAE [Linker et al.]. Furthermore, van Horssen et al. showed that invading leukocytes contribute to cell damage and demyelination by producing excessive amounts of cytotoxic mediators, including ROS, and that to neutralize the destructive effects of ROS, the CNS is endowed with a repertoire of endogenous antioxidant enzymes, which are regulated by the transcription factor Nrf2; on the basis of these findings, they suggested that persistent Nrf2-mediated transcription occurs in active MS lesions, but this endogenous response is insufficient to prevent ROS-induced cellular damage, which is abundant in inflammatory MS lesions [van Horssen et al.]. Accordingly, overexpression of Nrf2/ARE-regulated antioxidants in EAE and MS tissue is indicative of ongoing OS [Schreibelt et al., 2007]. Furthermore, Linker et al. reported the Nrf2 pathway was activated by dimethyl fumarate or monomethyl fumarate [Linker et al.]. They showed that dimethylfumarate exerts protective effects on oligodendrocytes, myelin, axons, and neurons in vivo and reduces the oxidative stress in MOG-EAE models; their study also provided evidence that the proper functioning of Nrf2 is required for the therapeutic effect of dimethylfumarate, suggesting that the CNS-protective effects of dimethylfumarate involve the activation of Nrf2-mediated OS response mechanisms, which is an important protective mechanism of the CNS in a variety of pathological conditions. A phase II trial is currently underway to examine the applicability of fumarate as a disease-modifying agent in MS patients [Barten et al., 2010].

6.3 Other extracts from plants to benefit MS

De Paula et al. found that genistein, which occurs abundantly in soy products, has apoptotic, antioxidant, and anti-inflammatory properties. They observed that genistein treatment significantly ameliorated the severity of EAE, modulating pro- and anti-inflammatory cytokines and decreasing the rolling and adhering of leukocytes, which imply that genistein may have potential as a therapeutic agent for MS [De Paula et al., 2008]. Another antioxidant compound, silymarin—a purified extract from milk thistle (*Silybum marianum*)—is composed of a mixture of 4 isomeric flavonolignans: silibinin (main active component), isosilibinin, silydianin, and silychristin. This extract has been empirically used as a remedy for almost 2000 years and continues to be used in the treatment of many types of acute and chronic liver diseases. Although it is routinely used in clinical practice as a hepatoprotectant, the mechanisms underlying its beneficial effects remain largely unknown [Crocenzi and Roma, 2006]. Min et al. reported that silibinin significantly reduced the histological signs of demyelination and inflammation in EAE and that silibinin downregulated the secretion of pro-inflammatory Th1 cytokines and upregulated the anti-inflammatory Th2 cytokines in vitro in an Ag-nonspecific manner. Further, silibinin dose-dependently inhibited the production of Th1 cytokines ex vivo, indicating that it is both immunosuppressive and immunomodulatory and may therefore be effective in the treatment of MS [Min et al., 2007].

Together, many antioxidant components extracted from natural foods or plants, such as flavonoids, luteolin, EGCG (extracted from green tea), genistein (occurring abundantly in

soy), and silibinin (the major pharmacologically active compound of silymarin, a fruit extract of *S. marianum*) have been proved to have not only health benefits but also the potential for use in the treatment of MS [Hutter and Laing, 1996; Mori et al., 2004; Sueoka et al., 2001; Theoharides, 2009].

7. Antioxidant and immunomodulatory effects of EPO in MS/EAE

EPO exhibits both hematopoietic and tissue-protective effects via interaction with different receptors [Leist et al., 2004].

Several experimental studies have shown that both EPO and EPO receptor (EpoR) are functionally expressed in the nervous system and that this cytokine has remarkable neuroprotective activity both in vitro, against different neurotoxins, and in vivo, in animal models of experimental nervous system disorders [Bartesaghi et al., 2005]. Moreover, EPO has been proved to have the ability to cross the BBB and modulate astrocytes to protect the brain from ischemic damage and the spinal cord from injury in animal models [Bernaudin et al., 1999; Brines et al., 2000; Diaz et al., 2005]. The neuroprotective effects of EPO against neuronal death induced by ischemia and hypoxia have also been extensively studied in both in vitro and in vivo studies [Bernaudin et al., 1999; Gunnarson et al., 2009].

7.1 Cytoprotective interaction of EPO and HO-1

A recent report indicated that the upregulation of HO-1 expression contributes to EPO-mediated cytoprotection against myocardial ischemia-reperfusion injury [Burger et al., 2009]. The neuroprotective action of EPO in ischemic and CNS degenerative models was mediated by Janus-tyrosine kinase 2 (Jak2) signaling and the subsequent activation of PI3-K/Akt phosphorylation and NF κ B cascades, which lead to the suppression of the CNS damage due to excitotoxins and the consequent generation of free radicals, including NO [Digicaylioglu and Lipton, 2001; Maiese et al., 2004]. Moreover, Sattler et al. showed that in rats with MOG-induced optic neuritis, the systemic administration of EPO resulted in a significant increase in the survival and function of retinal ganglion cells (RGC), the neurons that form the axons of the optic nerve; they also found that the neuroprotective effects of EPO were mediated by 3 independent intracellular signaling pathways involving the proteins phospho-Akt, phospho-MAPK 1 and 2, and Bcl-2m, which showed increased levels in vivo after EPO treatment [Sattler et al., 2004]. They also found that EPO in combination with a selective inhibitor of phosphatidylinositol 3-kinase (PI3-K) prevented the upregulation of phospho-Akt and the consecutive RGC rescue, thereby indicating that the PI3-K/Akt pathway in MOG-EAE has an essential influence on RGC survival under systemic EPO treatment [Sattler et al., 2004]. Interestingly, PI3K/Akt-pathway-related responses to OS and apoptosis have also been shown to be mediated by the transcriptional regulation of HO-1 [Martin et al., 2004]. Previously, Lifshitz et al. demonstrated that the dendritic cells (DCs) are direct targets of EPO, to initiate the immune response through the overexpression of human EPO in transgenic mice in in vivo experiments and validate a higher expression of EPO-R mRNA from bone marrow-derived DCs (BM-DCs) [Lifshitz et al., 2009]. Recent reports indicate that EPO exerts its cytoprotective effects in cardiac ischemia-reperfusion injury by inducing HO-1 expression [Burger et al., 2009].

7.2 Interaction of EPO, HO-1, and NO in EAE/MS

Tzima et al. reported that myeloid HO-1 deficiency exacerbated EAE in mice and enhanced the infiltration of activated macrophages and Th17 cells (IL-17-producing CD4⁺ IL-17-producing CD4⁺ T cells) in the CNS, and thus, they established HO-1 as a critical early mediator of the innate immune response [Tzima et al., 2009; Zwerina et al., 2005]. Liu showed that the inhibition of HO-1 expression resulted in marked exacerbation of EAE, suggesting that endogenous HO-1 expression plays an important protective role in EAE and that the targeted induction of HO-1 overexpression may represent a novel therapeutic strategy for the treatment of MS [Liu et al., 2001]. A study by Wu et al. at a center associated with ours revealed that the therapeutic induction of HO-1 expression ameliorates experimental murine membranous nephropathy via anti-oxidative, anti-apoptotic, and immunomodulatory mechanisms [Wu et al., 2008]. HO-1 overexpression has been proved to protect cells and tissues in a transgenic model of EAE [Panahian et al., 1999]. Moreover, Kumral et al. demonstrated that EPO exerts neuroprotective activity through the selective inhibition of NO overproduction in neonatal hypoxic-ischemic brain injury [Kumral et al., 2004]. Furthermore, Yuan et al. delineated a novel potential of EPO on peripheral inflammatory modulation in a murine MOG-EAE model [Yuan et al., 2008].

7.3 Immunomodulatory effects of EPO in EAE

After EPO was found to have neuroprotective effects in murine models of EAE [Zhang et al., 2005], it was introduced in humans and found to be effective in chronic progressive MS [Ehrenreich et al., 2007]. In our previous study, we found that EPO can enhance the expression of endogenous HO-1 either peripherally or locally in EAE; similarly, we observed that EPO-treated MOG-EAE mice exhibited upregulation of the splenic regulatory CD4⁺ T cells (Treg) and Th2 cells and downregulation of central Th1 and Th17 cells. We also obtained molecular evidence proving that EPO enhances the expression of endogenous HO-1 and that it has potential immunomodulatory activity and causes the suppression of inflammatory response to EAE [Chen et al., 2010].

We thus demonstrated the protective effects of EPO on EAE (Fig. 1a, b), and we observed significantly higher expression levels of endogenous HO-1 mRNA in the brain and a tendency for higher expression levels of endogenous HO-1 mRNA in the spinal cord and brain of the EPO-treated MOG-EAE mice than in those of the controls (Fig. 1c). Similarly, the expression levels of HO-1 mRNA in lymphocytes isolated from the CNS of MOG-EAE mice and controls differed significantly (Fig. 1c). Correspondingly, the protein levels of HO-1 in the spinal cord of EPO-treated MOG-EAE mice were higher than those of the controls (Fig. 1d). We further confirmed the augmenting effects of EPO on HO-1 *in situ*. Encephalitogenic Th17 cells play an essential role in the pathogenesis of EAE [Bettelli et al., 2006]. Th1 cells facilitate the invasion of Th17 cells to the CNS during EAE [O'Connor et al., 2008]. Further, IL-4 produced by CNS-derived Th2 cells is crucial to regulate the inflammation in EAE [Ponomarev et al., 2007]. To study the Th lineages further, we isolated mononuclear cells from the CNS of MOG-EAE mice treated with EPO and controls. Interestingly, we observed significantly lower ratios of both Th1 and Th17 cells to CD4⁺ cells in the EPO-treated MOG-EAE mice than in the controls; only a mildly increasing trend of encephalitogenic Th2 cells/CD4⁺ cells was noted in the EPO-treated group (Fig. 2 a-b). These findings suggest that EPO has the ability to counteract encephalitogenic Th1 and Th17 cells *in situ*, at least in part, and protect neuronal cells in EAE.

Fig. 1. EPO lessens EAE and enhances HO-1 *in situ*. (a) Clinical score and (b) time of onset of EAE in C57BL/6 mice treated i.p. with PBS or EPO (100 U/100 μ l/mouse) on days 1, 3, 5, and 7 after s.c. immunization with MOG₃₅₋₅₅/CFA on day 0 and PTX i.p. on days 0 and 2. Each group contained 10 mice. Data represent means $\pm$ SEM. (c) Expression of HO-1 mRNA in the brain, spinal cord, or lymphocytes isolated from CNS of EPO-treated and PBS-treated (as control) MOG-EAE mice determined by real time PCR. Data in plots are expressed as mean $\pm$ SD from 3 independent experiments. Statistical significance was set at $p < 0.05$. (d) Western blot analysis of HO-1 expression in the brain and spinal cord of EPO-treated and control mice on day 14 after MOG injection. (partly adapted from Clin Exp Immunol. [Chen et al.])

Furthermore, we observed a greater extent of staining for HO-1-positive splenocytes in EPO-treated MOG-EAE mice than in the controls (Fig. 3a); this was also reflected in a significantly greater mean fluorescence intensity (MFI) in flow cytometry of the splenic lymphocytes of EPO-treated MOG-EAE mice than those of the controls (Fig. 3b). Similarly, we found an increased ratio of encephalitogenic Th1 and Th17 cells in EPO-treated MOG-EAE mice, however, only a mildly decreasing trend of splenic Th1 and Th17 cell subsets from EPO-treated MOG-EAE mice was noted. Instead, a significantly high ratio of splenic Th2 (Fig. 3a) was noted in the EPO-treated group than in the controls, and a notably significant elevation of splenic CD25⁺Foxp3⁺ CD4⁺ cells (Tregs) was observed in the EPO-treated MOG-EAE mice (Fig. 3d).

We observed that the mRNA expression of HO-1 showed a tendency to increase, while the protein expression of HO-1 was notably high in the spinal cord of EPO-treated MOG-EAE; in contrast, a significant elevation of HO-1 mRNA, but no significant expression of HO-1 protein, was observed in the brain of EPO-treated MOG-EAE mice. Currently, Th17 cells are

Fig. 2. Distribution of Th lymphocyte subsets in situ. (a) Flow cytometric analysis of intracellular cytokines in CD4⁺ T cells isolated from CNS of mice treated with either EPO or PBS. CD4 T lymphocytes isolated from the CNS of EPO-treated mice or controls on day 21 at peak disease stage were intracellularly stained with IL-4, IFN-γ, and IL-17 by flow cytometry. (b) Percentages of IFN-γ-producing CD4⁺ T cells (Th1), IL-17-producing CD4⁺ T cells (Th17), and IL-4-producing CD4⁺ T cells (Th2) are presented. Data are representative of 3 experiments. (partly adapted from Clin Exp Immunol. [Chen et al.])

believed to play a vital role in immunopathogenic mechanisms of EAE. However, Th1 cells are required to facilitate the CNS infiltration of Th17 cells in EAE [O'Connor et al., 2008]. Yuan et al. reported that short-term EPO therapy for EAE can peripherally downregulate MHC class II of DCs and counteract Th17 cell responses [Yuan et al., 2008]. Our data confirmed further that EPO counteracts Th17 and Th1 cell inflammatory responses in EAE, both peripherally and centrally. EPO markedly reduced IL-6 levels in the spinal cord and decreased the inflammation and clinical score of EAE, thereby suggesting that the immunomodulatory activity of EPO may be partly mediated by the reduction of IL-6 levels

(b)

Fig. 3. EPO enhances splenic expression of HO-1, Th2 cells, and Treg.

(a) Immunohistochemical staining for HO-1 expression in the spleen of EPO-treated mice (right) and controls (left) on day 14 after MOG injection. Images are at either 40 × (top) or 400 × (bottom) magnification, and the length of the bar represents 50 μm. (b) Splenic lymphocytes from EPO-treated mice and controls on day 14 of EAE were stained with FITC-conjugated HO-1 for flow cytometry. Mean fluorescence intensity (MFI) of HO-1 staining was analyzed (b, left). Representative of 3 experiments. * indicates $p < 0.05$. (c) Splenic lymphocytes from EPO-treated mice and from controls were stained for Th1, Th2, and Th17 cells for flow cytometry analysis of the proportion of total CD4 T cells. Data represent 4 experiments. (d) These splenic lymphocytes were also stained for CD25⁺Foxp3⁺ CD4⁺ cells (Treg) by flow cytometry. Compared to controls, EPO-treated MOG-EAE mice had higher ratio of splenic Treg on day 14. Data of Treg represent 6 experiments. (partly adapted from Clin Exp Immunol. [Chen et al.])

[Agnello et al., 2002]. Tron et al. noted that the expression of HO-1 were elevated in a localized inflammation after intramuscular injection of inflammatory material and IL-6-specific transcripts were introduced into the injured muscle and were in accordance with the serum levels of IL-6; these findings imply that the induction of HO-1 in local inflammation may affect other anti-inflammatory agents, such as local IL-6 [Tron et al., 2005]. Our data show that there is suppression of IL-6 mRNA in the CNS of EPO-treated MOG-EAE mice, which may be attributed to the overexpression of residential HO-1 to counteract IL-6 (Fig. 2). However, further investigation is required to clarify this.

We confirmed that exogenous EPO promotes the expression of endogenous HO-1, either in the CNS or the spleen, to repress Th1 and Th17 responses *in situ* and that it enhances the systemic invasion of Th2 and Tregs to reduce the severity of EAE. The potential role of EPO in upregulating the expression of endogenous HO-1 and, thereby, the anti-oxidative and anti-inflammatory activities of HO-1 indicate that EPO may have potential for clinical therapeutic application in autoimmune CNS disorders, such as MS. Taken together, these findings suggested that EPO not only causes the upregulation of HO-1 expression in the CNS but also acts as a potent inducer of HO-1 expression in the peripheral immunologic systems. Collectively, the neuroprotective action of EPO in EAE appears to involve different mechanisms of systemic and local inhibition of inflammation [Chen et al., 2010].

8. Conclusion

Patients with MS often experience difficulty in ambulation, spasticity, sensation, and cognition. The year 2010 marked the beginning of the era of oral medications for MS with the introduction of fingolimod [Brinkmann et al., 2010] as the first oral disease-modifying agent for MS. Subsequently other oral agents, including cladribine, teriflunomide, laquinimod, and dimethyl fumarate, as well as the monoclonal antibodies alemtuzumab, daclizumab, and rituximab have been used in MS [Gold, Krieger]. Currently, promising results have been obtained in Phase II trials of teriflunomide, daclizumab, laquinimod, and an antioxidant agent-fumarate [Barten et al., 2010].

However, to date, no specific drugs have been developed to completely cure MS.

Considering the data gathered from studies, such as those on animal models of EAE, it can be inferred that antioxidant molecules may be beneficial to some extent for adjuvant therapy in MS [Mirshafiey and Mohsenzadegan, 2009; van Horssen et al., 2008; van Horssen et al., 2010]. Although some antioxidants have shown some degree of efficacy in EAE, little information is available on the effect of their use in MS [Mirshafiey and Mohsenzadegan, 2009; Schreibelt et al., 2007]. Nevertheless, antioxidant therapy can be considered a candidate for use as adjuvant therapy in MS.

9. Acknowledgments

This work was supported by grants from the TSGH-C101-009-S03 and to S.J. Chen, National Science Council, Taiwan, Republic of China (NSC 99-2314-B-016 -002 -MY3 to S.J. Chen) and National Science Council, Taiwan, Republic of China (NSC100-3112-B-016-001 to H.-K. Sytwu).

10. References

- Abdul HM, Butterfield DA (2007): Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. *Free Radic Biol Med* 42:371-84.
- Acuna CD, Escames G, Carazo A, Leon J, Khaldy H, Reiter RJ (2002): Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. *Curr Top Med Chem* 2:133-51.
- Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P (2002): Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. *Brain Res* 952:128-34.
- Akpınar D, Yargicoglu P, Derin N, Aliciguzel Y, Agar A (2008a): The effect of lipoic acid on antioxidant status and lipid peroxidation in rats exposed to chronic restraint stress. *Physiol Res* 57:893-901.
- Akpınar Z, Tokgoz S, Gokbel H, Okudan N, Uguz F, Yilmaz G (2008b): The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. *Psychiatry Res* 161:253-7.
- Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004): Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. *J Immunol* 173:5794-800.
- Anderson G, Rodriguez M (2011): Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. *Eur J Neurol* 18:680-5.
- Bal-Price A, Brown GC (2001): Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. *J Neurosci* 21:6480-91.
- Barten LJ, Allington DR, Procacci KA, Rivey MP (2010): New approaches in the management of multiple sclerosis. *Drug Des Devel Ther* 4:343-66.
- Bartesaghi S, Marinovich M, Corsini E, Galli CL, Viviani B (2005): Erythropoietin: a novel neuroprotective cytokine. *Neurotoxicology* 26:923-8.
- Bernaudo M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999): A potential role for erythropoietin in focal permanent cerebral ischemia in mice. *J Cereb Blood Flow Metab* 19:643-51.
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006): Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature* 441:235-8.
- Bever CT, Jr., Rosenberg GA (1999): Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? *Neurology* 53:1380-1.
- Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, Heales SJ (1997): Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. *J Neurochem* 68:2227-40.
- Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000): Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. *Proc Natl Acad Sci U S A* 97:10526-31.
- Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P (2010): Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* 9:883-97.

- Burger D, Xiang F, Hammoud L, Lu X, Feng Q (2009): Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion. *Am J Physiol Heart Circ Physiol* 296:H84-93.
- Castroviejo DA, Lopez LC, Escames G, Lopez A, Garcia JA, Reiter RJ (2011): Melatonin-mitochondria Interplay in Health and Disease. *Curr Top Med Chem* 11:221-40.
- Chaudhary P, Marracci GH, Bourdette DN (2006): Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. *J Neuroimmunol* 175:87-96.
- Chen SJ, Wang YL, Lo WT, Wu CC, Hsieh CW, Huang CF, Lan YH, Wang CC, Chang DM, Sytwu HK (2010): Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. *Clin Exp Immunol* 162:210-23.
- Cheng PY, Lee YM, Shih NL, Chen YC, Yen MH (2006): Heme oxygenase-1 contributes to the cytoprotection of alpha-lipoic acid via activation of p44/42 mitogen-activated protein kinase in vascular smooth muscle cells. *Free Radic Biol Med* 40:1313-22.
- Chora AA, Fontoura P, Cunha A, Pais TF, Cardoso S, Ho PP, Lee LY, Sobel RA, Steinman L, Soares MP (2007): Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. *J Clin Invest* 117:438-47.
- Colton CA, Gilbert DL (1993): Microglia, an in vivo source of reactive oxygen species in the brain. *Adv Neurol* 59:321-6.
- Constantinescu CS (1995): Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. *Med Hypotheses* 45:455-8.
- Constantinescu CS, Hilliard B, Ventura E, Rostami A (1997): Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. *Pathobiology* 65:190-4.
- Crocenzi FA, Roma MG (2006): Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. *Curr Med Chem* 13:1055-74.
- Cuzzocrea S, Costantino G, Mazzon E, Micali A, De Sarro A, Caputi AP (2000): Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. *J Pineal Res* 28:52-63.
- De Paula ML, Rodrigues DH, Teixeira HC, Barsante MM, Souza MA, Ferreira AP (2008): Genistein down-modulates pro-inflammatory cytokines and reverses clinical signs of experimental autoimmune encephalomyelitis. *Int Immunopharmacol* 8:1291-7.
- Diaz Z, Assaraf MI, Miller WH, Jr., Schipper HM (2005): Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. *J Neurochem* 93:392-402.
- Digicaylioglu M, Lipton SA (2001): Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. *Nature* 412:641-7.
- Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Siren AL, Paulus W, Nave KA, Gold R, Bartels C (2007): Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. *Brain* 130:2577-88.
- Emerit J, Edeas M, Bricaire F (2004): Neurodegenerative diseases and oxidative stress. *Biomed Pharmacother* 58:39-46.
- Emerson MR, LeVine SM (2000): Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response. *J Neurochem* 75:2555-62.

- Endoh M, Maiese K, Wagner J (1994): Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. *Brain Res* 651:92-100.
- Endres M (2006): Statins: potential new indications in inflammatory conditions. *Atheroscler Suppl* 7:31-5.
- Esposito E, Cuzzocrea S (2010): Antiinflammatory activity of melatonin in central nervous system. *Curr Neuropharmacol* 8:228-42.
- Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997): Axonal damage in acute multiple sclerosis lesions. *Brain* 120 (Pt 3):393-9.
- Floyd RA, Carney JM (1993): The role of metal ions in oxidative processes and aging. *Toxicol Ind Health* 9:197-214.
- Floyd RA, Hensley K (2002): Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. *Neurobiol Aging* 23:795-807.
- Frohman EM, Racke MK, Raine CS (2006): Multiple sclerosis--the plaque and its pathogenesis. *N Engl J Med* 354:942-55.
- Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL, Szabo C (1998): Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. *Faseb J* 12:685-93.
- Gilgun-Sherki Y, Melamed E, Offen D (2004): The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. *J Neurol* 251:261-8.
- Gohil K, Roy S, Packer L, Sen CK (1999): Antioxidant regulation of gene expression: analysis of differentially expressed mRNAs. *Methods Enzymol* 300:402-10.
- Gold R (2011): Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. *CNS Drugs* 25:37-52.
- Golde S, Chandran S, Brown GC, Compston A (2002): Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression. *J Neurochem* 82:269-82.
- Gray E, Thomas TL, Betmouni S, Scolding N, Love S (2008): Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. *Brain Pathol* 18:86-95.
- Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, Cerami A, Andersson U, Zelenina M, Aperia A (2009): Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. *Proc Natl Acad Sci U S A* 106:1602-7.
- Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE (2004): Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. *J Exp Med* 200:1667-72.
- Hendriks JJ, de Vries HE, van der Pol SM, van den Berg TK, van Tol EA, Dijkstra CD (2003): Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. *Biochem Pharmacol* 65:877-85.
- Hill JM, Switzer RC, 3rd (1984): The regional distribution and cellular localization of iron in the rat brain. *Neuroscience* 11:595-603.
- Hisahara S, Okano H, Miura M (2003): Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. *Neurosci Res* 46:387-97.
- Hutter CD, Laing P (1996): Multiple sclerosis: sunlight, diet, immunology and aetiology. *Med Hypotheses* 46:67-74.
- Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC (2008): The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. *Ann N Y Acad Sci* 1147:61-9.

- Kalman B, Laitinen K, Komoly S (2007): The involvement of mitochondria in the pathogenesis of multiple sclerosis. *J Neuroimmunol* 188:1-12.
- Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T (2001): Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. *J Vet Sci* 2:85-9.
- Kaur C, Ling EA (2008): Antioxidants and neuroprotection in the adult and developing central nervous system. *Curr Med Chem* 15:3068-80.
- Kornek B, Storch MK, Weissert R, Wallstroem E, Steffler A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000): Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. *Am J Pathol* 157:267-76.
- Krieger S (2011): Multiple sclerosis therapeutic pipeline: opportunities and challenges. *Mt Sinai J Med* 78:192-206.
- Kumral A, Baskin H, Gokmen N, Yilmaz O, Genc K, Genc S, Tatli MM, Duman N, Ozer E, Ozkan H (2004): Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? *Biol Neonate* 85:51-4.
- Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA (2005): Nrf2, a multi-organ protector? *Faseb J* 19:1061-6.
- Lee S, Suk K (2007): Heme oxygenase-1 mediates cytoprotective effects of immunostimulation in microglia. *Biochem Pharmacol* 74:723-9.
- Lee TS, Chau LY (2002): Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. *Nat Med* 8:240-6.
- Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004): Derivatives of erythropoietin that are tissue protective but not erythropoietic. *Science* 305:239-42.
- Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D (2009): Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. *Mol Immunol* 46:713-21.
- Lin GJ, Huang SH, Chen YW, Hueng DY, Chien MW, Chia WT, Chang DM, Sytwu HK (2009): Melatonin prolongs islet graft survival in diabetic NOD mice. *J Pineal Res* 47:284-92.
- Lin RF, Lin TS, Tilton RG, Cross AH (1993): Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. *J Exp Med* 178:643-8.
- Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011): Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain* 134:678-92.
- Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS (2001): Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. *Neuroreport* 12:1841-5.
- Liuzzi GM, Latronico T, Brana MT, Gramegna P, Coniglio MG, Rossano R, Larocca M, Riccio P (2011): Structure-dependent inhibition of gelatinases by dietary

- antioxidants in rat astrocytes and sera of multiple sclerosis patients. *Neurochem Res* 36:518-27.
- Maestroni GJ (1995): T-helper-2 lymphocytes as a peripheral target of melatonin. *J Pineal Res* 18:84-9.
- Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM (2009): Mitochondrial changes within axons in multiple sclerosis. *Brain* 132:1161-74.
- Maiese K, Li F, Chong ZZ (2004): Erythropoietin in the brain: can the promise to protect be fulfilled? *Trends Pharmacol Sci* 25:577-83.
- Mander P, Borutaite V, Moncada S, Brown GC (2005): Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. *J Neurosci Res* 79:208-15.
- Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA (2001): Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. *Brain* 124:493-8.
- Marangon K, Devaraj S, Tirosh O, Packer L, Jialal I (1999): Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. *Free Radic Biol Med* 27:1114-21.
- Marracci GH, Jones RE, McKeon GP, Bourdette DN (2002): Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. *J Neuroimmunol* 131:104-14.
- Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK, Bourdette DN (2004): Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. *J Neurosci Res* 78:362-70.
- Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A (2004): Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. *J Biol Chem* 279:8919-29.
- Martin M, Macias M, Escames G, Leon J, Acuna-Castroviejo D (2000): Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. *Faseb J* 14:1677-9.
- Min K, Yoon WK, Kim SK, Kim BH (2007): Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. *Arch Pharm Res* 30:1265-72.
- Mirshafiey A, Mohsenzadegan M (2009): Antioxidant therapy in multiple sclerosis. *Immunopharmacol Immunotoxicol* 31:13-29.
- Moi P, Chan K, Asunis I, Cao A, Kan YW (1994): Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proc Natl Acad Sci U S A* 91:9926-30.
- Moini H, Packer L, Saris NE (2002): Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. *Toxicol Appl Pharmacol* 182:84-90.
- Mori A, Yokoi I, Noda Y, Willmore LJ (2004): Natural antioxidants may prevent posttraumatic epilepsy: a proposal based on experimental animal studies. *Acta Med Okayama* 58:111-8.
- Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albin A, Uccelli A (2004): Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 148:146-53.

- Murakami A (2009): Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. *Forum Nutr* 61:193-203.
- Murphy MP (1999): Nitric oxide and cell death. *Biochim Biophys Acta* 1411:401-14.
- Nath N, Giri S, Prasad R, Singh AK, Singh I (2004): Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. *J Immunol* 172:1273-86.
- O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, Anderton SM (2008): Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. *J Immunol* 181:3750-4.
- Okuda Y, Sakoda S, Fujimura H, Yanagihara T (1997): Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with experimental allergic encephalomyelitis. *J Neuroimmunol* 73:107-16.
- Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997): Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. *J Clin Invest* 100:2671-9.
- Panahian N, Yoshiura M, Maines MD (1999): Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. *J Neurochem* 72:1187-203.
- Paz Soldan MM, Pittcock SJ, Weigand SD, Yawn BP, Rodriguez M (2011): Statin therapy and multiple sclerosis disability in a population-based cohort. *Mult Scler*. Epub ahead of print.
- Pierpaoli W, Regelson W (1994): Pineal control of aging: effect of melatonin and pineal grafting on aging mice. *Proc Natl Acad Sci U S A* 91:787-91.
- Ponomarev ED, Maresz K, Tan Y, Dittel BN (2007): CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. *J Neurosci* 27:10714-21.
- Prawan A, Kundu JK, Surh YJ (2005): Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. *Antioxid Redox Signal* 7:1688-703.
- Reiter RJ (1995a): Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. *Front Neuroendocrinol* 16:383-415.
- Reiter RJ (1995b): Oxidative processes and antioxidative defense mechanisms in the aging brain. *Faseb J* 9:526-33.
- Reiter RJ, Tan DX, Manchester LC, Tamura H (2007): Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. *J Physiol Pharmacol* 58 Suppl 6:5-22.
- Rushmore TH, Morton MR, Pickett CB (1991): The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. *J Biol Chem* 266:11632-9.
- Rushmore TH, Pickett CB (1990): Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. *J Biol Chem* 265:14648-53.
- Sandyk R (1997): Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: possible relationship to the acquisition of multiple sclerosis. *Int J Neurosci* 90:129-33.

- Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, Diem R (2004): Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. *Cell Death Differ* 11 Suppl 2:S181-92.
- Schipper HM (2004): Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress. *Ann N Y Acad Sci* 1012:84-93.
- Schluesener HJ, Seid K (2000): Heme oxygenase-1 in lesions of rat experimental autoimmune encephalomyelitis and neuritis. *J Neuroimmunol* 110:114-20.
- Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendriks EM, Dopp ED, Dijkstra CD, Drukarch B, de Vries HE (2006): Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. *J Immunol* 177:2630-7.
- Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007): Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. *Brain Res Rev* 56:322-30.
- Schreiner B, Heppner FL, Becher B (2009): Modeling multiple sclerosis in laboratory animals. *Semin Immunopathol* 31:479-95.
- Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmstrom C, Stenager E, Sellebjerg F, Sondergaard HB (2011): Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. *Lancet Neurol* 10:691-701.
- Stanislaus R, Pahan K, Singh AK, Singh I (1999): Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. *Neurosci Lett* 269:71-4.
- Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, Munschauer F (2008): Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. *J Neuroimmunol* 205:142-7.
- Su KG, Banker G, Bourdette D, Forte M (2009): Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. *Curr Neurol Neurosci Rep* 9:411-7.
- Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, Imai K, Nakachi K, Fujiki H (2001): A new function of green tea: prevention of lifestyle-related diseases. *Ann N Y Acad Sci* 928:274-80.
- Taupin P (2008): Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. *Int J Med Sci* 5:127-32.
- Theoharides TC (2009): Luteolin as a therapeutic option for multiple sclerosis. *J Neuroinflammation* 6:29.
- Tirosh O, Sen CK, Roy S, Kobayashi MS, Packer L (1999): Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue. *Free Radic Biol Med* 26:1418-26.
- Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998): Axonal transection in the lesions of multiple sclerosis. *N Engl J Med* 338:278-85.
- Tron K, Novosyadlyy R, Dudas J, Samoylenko A, Kietzmann T, Ramadori G (2005): Upregulation of heme oxygenase-1 gene by turpentine oil-induced localized inflammation: involvement of interleukin-6. *Lab Invest* 85:376-87.
- Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G (2009): Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. *J Exp Med* 206:1167-79.

- van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, Dijkstra CD (1998): Reactive oxygen species are required for the phagocytosis of myelin by macrophages. *J Neuroimmunol* 92:67-75.
- van der Valk P, De Groot CJ (2000): Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. *Neuropathol Appl Neurobiol* 26:2-10.
- van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, de Vries HE (2010): Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. *Free Radic Biol Med* 49:1283-9.
- van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE (2008): Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. *Free Radic Biol Med* 45:1729-37.
- van Horssen J, Witte ME, Schreibelt G, de Vries HE (2011): Radical changes in multiple sclerosis pathogenesis. *Biochim Biophys Acta* 1812:141-50.
- van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EA (2005): Antioxidants and polyunsaturated fatty acids in multiple sclerosis. *Eur J Clin Nutr* 59:1347-61.
- Venugopal R, Jaiswal AK (1996): Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. *Proc Natl Acad Sci U S A* 93:14960-5.
- Verbeek R, van Tol EA, van Noort JM (2005): Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. *Biochem Pharmacol* 70:220-8.
- Weber MS, Zamvil SS (2008): Statins and demyelination. *Curr Top Microbiol Immunol* 318:313-24.
- Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries HE, van der Valk P, van Horssen J (2009): Enhanced number and activity of mitochondria in multiple sclerosis lesions. *J Pathol* 219:193-204.
- Wu CC, Lu KC, Chen JS, Hsieh HY, Lin SH, Chu P, Wang JY, Sytwu HK, Lin YF (2008): HO-1 induction ameliorates experimental murine membranous nephropathy: anti-oxidative, anti-apoptotic and immunomodulatory effects. *Nephrol Dial Transplant* 23:3082-90.
- Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002): The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. *Nature* 420:78-84.
- Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P (2008): Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. *PLoS ONE* 3:e1924.
- Zenclussen ML, Anegón I, Bertoja AZ, Chauveau C, Vogt K, Gerlof K, Sollwedel A, Volk HD, Ritter T, Zenclussen AC (2006): Over-expression of heme oxygenase-1 by adenoviral gene transfer improves pregnancy outcome in a murine model of abortion. *J Reprod Immunol* 69:35-52.
- Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, Chopp M (2005): Erythropoietin treatment improves neurological functional recovery in EAE mice. *Brain Res* 1034:34-9.
- Zwerina J, Tzima S, Hayer S, Redlich K, Hoffmann O, Hanslik-Schnabel B, Smolen JS, Kollias G, Schett G (2005): Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. *Faseb J* 19:2011-3.

Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy

Edited by Prof. Robert Weissert

ISBN 978-953-51-0038-6

Hard cover, 162 pages

Publisher InTech

Published online 03, February, 2012

Published in print edition February, 2012

Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy is totally focused on the model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). The book chapters give a very good and in depth overview about the currently existing and most used EAE models. In addition, chapters dealing with novel experimental therapeutic approaches demonstrate the usefulness of the EAE model for MS research. With an international perspective, this book features contributions from authors throughout the world, Australia, Germany, Japan, Spain, Taiwan, and USA. There is an impressive international Faculty that provides insight into current research themes. This further demonstrates the importance of EAE in research all over the world. The book will provide established researchers and students with novel insights and guidance for their research and will help to push the field forward.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Shyi-Jou Chen Hueng-Chuen Fan and Huey-Kang Sytwu (2012). Immunomodulation of Potent Antioxidant Agents: Preclinical Study to Clinical Application in Multiple Sclerosis, Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy, Prof. Robert Weissert (Ed.), ISBN: 978-953-51-0038-6, InTech, Available from: <http://www.intechopen.com/books/experimental-autoimmune-encephalomyelitis-models-disease-biology-and-experimental-therapy/immunomodulation-of-potent-antioxidant-agents-from-preclinical-study-to-clinical-application-on-mult>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.